Compass Therapeutics Receives FDA Recommendation for Additional Clinical Trial for Tovecimig

Filing content

The FDA recommended that the company conduct a trial to demonstrate survival benefit before submitting a BLA for tovecimig, though the company intends to engage further with the FDA based on existing data.